Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Kalyan Banda"'
Autor:
Heidi J. Gray, Payel Chatterjee, Rachele Rosati, Lauren R. Appleyard, Grace J. Durenberger, Robert L. Diaz, Hallie A. Swan, Danielle Peretti, Maddy Pollastro, Trevor Ainge, Katannya Kapeli, Shalini Pereira, Astrid L. Margossian, Kalyan Banda, Barbara A. Goff, Elizabeth M. Swisher, Brady Bernard, Christopher J. Kemp, Carla Grandori
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-6 (2023)
Abstract Low-grade serous ovarian cancer (LGSOC) typically responds poorly to standard platinum-based chemotherapy and new therapeutic approaches are needed. We describe a remarkable response to targeted therapy in a patient with platinum-resistant,
Externí odkaz:
https://doaj.org/article/8a9cc59b3ce64630836df3b6b10cdaf8
Autor:
Niklas Krumm, Nithisha S. Khasnavis, Marc Radke, Kalyan Banda, Helen R. Davies, Christopher Pennil, Kathryn McLean, Vera A. Paulson, Eric Q. Konnick, Winslow C. Johnson, Grogan Huff, Serena Nik-Zainal, Elizabeth M. Swisher, Christina M. Lockwood, Stephen J. Salipante
Publikováno v:
JCO Precision Oncology.
PURPOSE Homologous recombination DNA repair deficiency (HRD) is a therapeutic biomarker for sensitivity to platinum and poly(ADP-ribose) polymerase inhibitor therapies in breast and ovarian cancers. Several molecular phenotypes and diagnostic strateg
Autor:
Meghan R. Flanagan, David R. Doody, Jenna Voutsinas, Qian Wu, Kalyan Banda, Nima Sharifi, Christopher I. Li, Vijayakrishna K. Gadi
Publikováno v:
Annals of Surgical Oncology. 29:7194-7201
Publikováno v:
Clinical Breast Cancer. 22:e310-e318
Background Anthracycline and taxane-based doublets have largely replaced cyclophosphamide, methotrexate, and fluorouracil (CMF) as preferred regimens in the adjuvant treatment of breast cancer. Metronomic CMF is associated with improved tolerability
Autor:
Francesca, Menghi, Kalyan, Banda, Pooja, Kumar, Robert, Straub, Lacey, Dobrolecki, Isabel V, Rodriguez, Susan E, Yost, Harshpreet, Chandok, Marc R, Radke, George, Somlo, Yuan, Yuan, Michael T, Lewis, Elizabeth M, Swisher, Edison T, Liu
Publikováno v:
Science translational medicine. 14(652)
Triple-negative breast cancer (TNBC) and ovarian carcinomas (OvCas) with
Autor:
Francesca Menghi, Kalyan Banda, Pooja Kumar, Robert Straub, Lacey Dobrolecki, Isabel V. Rodriguez, Susan E. Yost, Harshpreet Chandok, Marc R. Radke, George Somlo, Yuan Yuan, Michael T. Lewis, Elizabeth M. Swisher, Edison T. Liu
Publikováno v:
Science Translational Medicine. 14
Triple-negative breast cancer (TNBC) and ovarian carcinomas (OvCas) with BRCA1 promoter methylation ( BRCA1 meth) respond more poorly to alkylating agents compared to those bearing mutations in BRCA1 and BRCA2 ( BRCA mut). This is a conundrum given t
Autor:
Amanda M. Prechtl, Marwah Al-Aloosi, Payel Chatterjee, Rachele Rosati, Samantha Velazquez, Lauren Appleyard, Grace Durenberger, Cristina Cordero, Robert Diaz, Hallie Swan, Brady Bernard, Siddhartha Mukherjee, Barbara Goff, Elizabeth Swisher, Heidi Gray, Kalyan Banda, Christopher Kemp, Carla Grandori
Publikováno v:
Cancer Research. 83:3399-3399
Background: Over 50% of patients with ovarian cancer (OVCA) succumb to their disease within five years from diagnosis, highlighting the need for new approaches to identify therapeutic options. The PARIS® test is a CLIA certified organoid based high
Autor:
Francesca Menghi, Kalyan Banda, Pooja Kumar, Robert Straub, Lacey E. Dobrolecki, Isabel Rodriguez, Susan E. Yost, Harshpreet Chandok, Marc Radke, George Somlo, Yuan Yuan, Michael T. Lewis, Elizabeth Swisher, Edison Liu
Publikováno v:
Cancer Research. 83:PD5-01
Background. Homologous recombination deficiency (HRD), induced by germline and somatic BRCA1 or BRCA2 gene mutations (BRCAmut) and by BRCA1 promoter methylation (BRCA1meth), has been associated with better response to platinum agents in both triple n
Autor:
Meghan R. Flanagan, David R. Doody, Jenna Voutsinas, Qian Wu, Kalyan Banda, Nima Sharifi, Christopher I. Li, Vijayakrishna K. Gadi
Publikováno v:
Annals of Surgical Oncology. 29:7204-7205
Publikováno v:
JCO precision oncology. 2